Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?


OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary


Nurix Therapeutics is owned by 10.80% institutional investors, 1.09% insiders, and 88.11% retail investors. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.16% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNurix Therapeutics10.80%1.09%88.11%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock6.82M12.42%$142.33M
Fmr8.89M10.56%$82.12M
Blackrock funding, inc. /de6.76M8.04%$62.49M
Deep track capital, lp6.06M7.20%$55.97M
Vanguard group4.49M5.33%$41.48M
Baker bros. advisors lp3.88M4.61%$35.87M
Commodore capital lp3.78M4.49%$34.93M
Redmile group3.68M4.37%$33.99M
Vestal point capital, lp3.48M4.13%$32.11M
Point72 asset management2.87M3.41%$26.53M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group3.68M3.31%$33.99M
Commodore capital lp3.78M1.71%$34.93M
Deep track capital, lp6.06M1.56%$55.97M
Kynam capital management, lp2.17M1.49%$20.04M
Vestal point capital, lp3.48M1.45%$32.11M
Soleus capital management2.42M1.13%$22.39M
Patient square capital lp437.24K1.08%$4.04M
Affinity asset advisors967.62K0.78%$8.94M
Boxer capital management175.00K0.52%$1.62M
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group85.00K0.46%$785.40K

Top Buyers

HolderShares% AssetsChange
Blackrock6.82M0.00%2.24M
Vestal point capital, lp3.48M1.45%1.48M
Deutsche bank ag\1.44M0.00%1.07M
Kynam capital management, lp2.17M1.49%995.00K
Algert global563.84K0.09%449.34K

Top Sellers

HolderShares% AssetsChange
Price t rowe associates inc /md/1.10M0.00%-1.93M
Fmr8.89M0.00%-1.55M
Ra capital management---1.33M
T. rowe price investment management1.20M0.01%-1.28M
Ubs group362.55K0.00%-1.23M

New Positions

HolderShares% AssetsChangeValue
Norges bank318.80K0.00%318.80K$6.01M
Jane street group258.65K0.00%258.65K$2.39B
Marshall wace, llp246.79K0.00%246.79K$2.28M
Connor, clark & lunn investment management61.52K0.00%61.52K$568.40M
Lighthouse investment partners50.00K0.01%50.00K$462.00K

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
True wealth design-4.00
Ifp advisors-6.00
Nelson, van denburg & campbell wealth management group-9.00
Federated hermes-15.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202546-72.12%9,091,319-89.71%100.10%18-80.43%17-59.52%
Jun 30, 2025164-4.09%88,304,1285.07%1051.04%91-3.19%42-17.65%
Mar 31, 2025171-3.93%84,588,6764.29%1010.69%93-11.43%5110.87%
Dec 31, 20241771.72%81,111,27120.04%1201.40%1039.57%47-16.07%
Sep 30, 2024174-1.14%67,568,4773.95%920.66%94-16.81%5624.44%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.42M3.16%-53.57K
Vanguard US Total Market Shares ETF2.13M2.79%196.50K
iShares Russell 2000 ETF1.82M2.38%-
Fidelity Select Health Care1.69M2.21%90.00K
ARK Genomic Revolution1.54M2.01%-28.29K
ARK Genomic Revolution ETF1.53M2.01%-5.47K
Amova ARK Pstv Chg Innovt P JPY Acc1.42M1.86%322.21K
US Small-Cap Growth II Equity Comp1.35M1.76%14.21K
Nikko AM ARK Pstv Chg Innovt P JPY Acc1.10M1.44%273.18K
T. Rowe Price Integrated US SmCapGrEq985.71K1.39%492.85K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 24, 2025Ring Christine Chief Legal OfficerSell$641.70K
Nov 03, 2025van Houte Hans Chief Financial OfficerSell$78.93K
Oct 30, 2025van Houte Hans Chief Financial OfficerSell$40.05K
Oct 30, 2025Ring Christine Chief Legal OfficerSell$46.63K
Oct 30, 2025Hansen Gwenn Chief Scientific OfficerSell$52.30K

Insider Transactions Trends


DateBuySell
2025 Q4-5
2025 Q3-4
2025 Q2-4
2025 Q1-11
2024 Q4-10

NRIX Ownership FAQ


Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 10.80%, followed by 1.09% insiders and 88.11% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 45.24%, which Nurix Therapeutics falls below.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Fmr (8.89M shares, 10.56%), and Blackrock funding, inc. /de (6.76M shares, 8.04%). Together, they hold 31.02% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.31% of its assets in 3.68M Nurix Therapeutics shares, valued at 33.99M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nurix Therapeutics shares, with 3.16% of its total shares outstanding invested in 2.42M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools